Stock MSCL SATELLOS BIOSCIENCE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 02:55:45 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.48 CAD +9.09% Intraday chart for Satellos Bioscience Inc. -7.69% +11.63%
Mar. 27 Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 27 Satellos Bioscience Announces FY 2023 Results MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 6.782 36.58 39.55 - -
Enterprise Value (EV) 1 6.782 36.58 39.55 39.55 39.55
P/E ratio - - -2.53 x -2.4 x -2.67 x
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA - - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 41,798 112,792 112,792 - -
Reference price 2 0.2200 0.4300 0.4800 0.4800 0.4800
Announcement Date 3/30/23 3/27/24 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -6.268 -11.38 -15.7 -11.9 -19.76
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -8.363 -11.69 -15.7 -11.85 -19.76
Net income 1 -8.368 -11.69 -15.7 -11.85 -19.76
Net margin - - - - -
EPS 2 - - -0.1900 -0.2000 -0.1800
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 3/30/23 3/27/24 - - -
1USD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 - -1.419 -1.593 -1.229 -3.209 -3.268 -4.598 -4.038 -3.849 -3.887 -3.926 -
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - -1.418 -3.744 -1.225 -3.026 -2.602 -4.809 -4.038 -3.849 -3.887 -3.926 -
Net income 1 -1.719 -1.418 -3.748 -1.225 -3.026 -2.602 -4.809 -4.038 -3.849 -3.887 -3.926 -
Net margin - - - - - - - - - - - -
EPS 2 - - - - - - - -0.0500 -0.0500 -0.0500 -0.0500 -0.0500
Dividend per Share - - - - - - - - - - - -
Announcement Date 8/29/22 11/23/22 3/30/23 5/30/23 8/28/23 11/22/23 3/27/24 - - - - -
1USD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 3/30/23 3/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.48 CAD
Average target price
1.2 CAD
Spread / Average Target
+150.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SATELLOS BIOSCIENCE INC. Stock Satellos Bioscience Inc.
+11.63% 39.55M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MSCL Stock
  4. Financials Satellos Bioscience Inc.